What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2025-03-10 compared with 2025-02-19 · 204 added, 147 removed, 132 unchanged (73% of the section changed)

2 unchanged sentences

Forward-Looking Statements

This Amendment contains certain statements

that constitute forward-looking statements.

Any and all statements contained in this Amendment that are not statements of historical

fact may be deemed forward-looking statements.

This Amendment contains certain statements that

constitute forward-looking statements.

Any and all statements contained in this Amendment that are not statements of historical fact may

be deemed forward-looking statements.

Terms such as “ may ,” “ might ,” “ would ,”

15 unchanged sentences

and Results of Operations .” in our 2023 Form 10-K, as amended.

Forward-looking statements in this Amendment

may include, without limitation, statements regarding:

plans and objectives of management for future operations, including plans or objectives relating

to the marketing of our surgical robotic systems both in and out of India;

timing or likelihood of regulatory filing, approvals and required licenses for marketing

our surgical robotic systems in the U.S., the European Union (the “ EU ”)

and in other countries outside of India;

ability to adequately protect our intellectual property rights and enforce such rights to

avoid violation of the intellectual property rights of others;

timing, costs and other aspects of our surgical robotic systems;

estimates regarding the market opportunity, clinical utility, potential advantages and market

acceptance of our surgical robotic systems;

impact of government laws and regulations;

ability to recruit and retain qualified research and development personnel;

(viii) difficulties

in maintaining commercial scale manufacturing capacity and capability and our ability to

generate growth;

(ix) uncertainty

in industry demand;

economic conditions and market conditions in our industry;

projection of income (including income/loss), earnings (including earnings/loss) per share,

capital expenditures, dividends, capital structure or other financial items;

future financial performance, including any such statement contained in a discussion and

analysis of financial condition by management or in the results of operations included pursuant

to the rules and regulations of the SEC;

(xiii) Changes

resulting from the restatement of our condensed consolidated financial statements included

in this Report.

Forward-looking statements in this Amendment may

include, without limitation, statements regarding:

the plans and objectives of management for future operations, including plans or objectives relating to the marketing of our surgical robotic systems both in and out of India;

the timing or likelihood of regulatory filing, approvals and required licenses for marketing our surgical robotic systems in the U.S., the European Union (the “ EU ”) and in other countries outside of India;

our ability to adequately protect our intellectual property rights and enforce such rights to avoid violation of the intellectual property rights of others;

the timing, costs and other aspects of our surgical robotic systems;

our estimates regarding the market opportunity, clinical utility, potential advantages and market acceptance of our surgical robotic systems;

the impact of government laws and regulations;

our ability to recruit and retain qualified research and development personnel;

difficulties in maintaining commercial scale manufacturing capacity and capability and our ability to generate growth;

uncertainty in industry demand;

general economic conditions and market conditions in our industry;

a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items;

our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC;

Changes resulting from the restatement of our condensed consolidated financial statements included in this Report.

These statements are not guarantees of future

14 unchanged sentences

” (“ AVRA ”) on November 5, 2015.

From inception through April 13, 2023, we

were engaged in developing a fully autonomous medical robotic system using proprietary software which integrated Artificial Intelligence

and Deep Learning, or Machine Learning.

From inception through April 13, 2023, we were

engaged in developing a fully autonomous medical robotic system using proprietary software which integrated Artificial Intelligence and

Deep Learning, or Machine Learning.

Our research and development efforts were based in Orlando, Florida, where we established a research

2 unchanged sentences

of Cardio Ventures, Inc.

(“CardioVentures) began discussions to explore potential merger synergies, leading to a formal agreement

in November 2022 by and among the Company, a wholly owned subsidiary of the Company (“ Merger Sub ”), CardioVentures

Sudhir Srivastava, who, through his holding company, owned a controlling interest in CardioVentures (“Merger Agreement”).

(“ CardioVentures ”) began discussions to explore potential merger synergies, leading to a

formal agreement in November 2022 by and among the Company, a wholly owned subsidiary of the Company (“ Merger Sub ”),

CardioVentures and Dr.

Sudhir Srivastava, who, through his holding company, owned a controlling interest in CardioVentures (the “ Merger

Agreement ”).

Cardio Ventures was primarily seeking a platform to raise funds in the U.S.

to support operations of its subsidiary, SSI India.

ability to attract funds from its high-net-worth investors became a focal point in these discussions, presenting a path for AVRA shareholders

to also benefit from the merger.

Consequently, as part of the merger strategy, AVRA raised funds through convertible notes (at the rate

of 7% interest per annum), which were subsequently provided to Cardio Ventures via convertible notes issued by Cardio Ventures.

like Andrew Economos and Dr.

Fred Moll, both existing AVRA shareholders, contributed to these notes, foreseeing significant commercial

benefits and the potential for AVRA’s turnaround post-merger, despite AVRA’s status as an inactive company at the time.

April 14, 2023, we consummated the acquisition of by merger of CardioVentures, Inc., pursuant to the Merger Agreement.

to support operations of its subsidiary,

AVRA’s ability to attract funds from its high-net-worth investors became a focal point in these discussions, presenting

a path for AVRA shareholders to also benefit from the merger.

Consequently, as part of the merger strategy, AVRA raised funds through

convertible notes (at the rate of 7% interest per annum), which were subsequently provided to Cardio Ventures via convertible notes issued

by Cardio Ventures.

Investors like Andrew Economos and Dr.

Fred Moll, both existing AVRA shareholders, contributed to these notes, foreseeing

significant commercial benefits and the potential for AVRA’s turnaround post-merger, despite AVRA’s status as an inactive

company at the time.

On April 14, 2023, we consummated the acquisition of by merger of CardioVentures, pursuant to the Merger Agreement.

The Company is currently engaged in the business

4 unchanged sentences

April 2023, when compared with operating results for the corresponding period in 2022.

Our financial performance is largely driven

by increasing awareness of the benefits of robotically assisted surgery, improved learning curves for robotic surgeons and the affordability

Our financial performance is largely driven by

increasing awareness of the benefits of robotically assisted surgery, improved learning curves for robotic surgeons and the affordability

and accessibility of surgical robotic technology.

1 unchanged sentence

various regulated markets where we have plans to sell our products.

Robotically assisted surgeries are increasingly being recognized

as an approved treatment modality from an insurance coverage perspective.

Our manufacturing operations being based in

India derive significant operating cost advantages in terms of availability of quality and cost-effective fabrication/3D printing solutions,

Robotically assisted surgeries are increasingly being recognized as

an approved treatment modality from an insurance coverage perspective.

Our manufacturing operations being based in India

derive significant operating cost advantages in terms of availability of quality and cost-effective fabrication/3D printing solutions,

electronic/electrical/mechanical components, outsourced services and skilled manpower.

5 unchanged sentences

the Company commercially launched its “ SSI Mantra ” robotic surgical system in India.

During the three months ended

March 31, 2024, we have sold 5 systems, which have performed more than 230 procedures of various types involving varying degrees of complexities.

During the six months and three

months period ended June 30, 2024, we have sold 14 and 9 systems respectively, which have performed more than 230 procedures of various

types involving varying degrees of complexities.

Results of Operations

The following discussion should be read in

conjunction with our condensed consolidated financial statement and Notes thereto.

This section of the Report generally discusses 2024

and 2023 items and quarter-to- quarter comparisons between 2024 and 2023.

The following discussion should be read in conjunction

with our condensed consolidated financial statement and Notes thereto.

This section of the Report generally discusses 2024 and 2023 items

and quarter-to- quarter comparisons between 2024 and 2023.

The Company has recently commenced its commercial

1 unchanged sentence

operating costs and hence may continue to incur losses for some time.

These conditions raise doubt about the Company’s ability

to continue as a going concern.

The financial statements appearing elsewhere

in this report have been prepared assuming that the Company will continue as a going concern.

These conditions raise doubt about the Company’s ability to

continue as a going concern.

The financial statements appearing elsewhere in

this report have been prepared assuming that the Company will continue as a going concern.

The following table provides selected balance

sheet data for our Company as of March 31, 2024, and December 31, 2023:

sheet data for our Company as of June 30, 2024, and December 31, 2023:

Balance Sheet Data

3 unchanged sentences

Total liabilities and stockholders’ equity

Fixed Deposits held by bank as security for bank facilities and certain performance guarantees.

Represents Fixed Deposits held by bank as security for bank facilities and certain performance guarantees.

To date, the Company has mainly relied on

debt and equity raised in private offerings to finance its operations.

Subsequent to March 2024, the Company plans to raise additional

capital through further private or public offerings.

However, if we are unable to do so and if we experience a shortfall in operating

capital, we could be faced with having to limit our expansion plans, research and development and marketing activities

the Three months ended

Subsequent to June 2024, the Company has raised $23,000,000 through

its affiliates till January 2025, and the Company plans to raise additional capital through further private or public offerings.

if we are unable to do so and if we experience a shortfall in operating capital, we could be faced with having to limit our expansion

plans, research and development and marketing activities

For the three months ended

(As restated)

Total Revenue

Cost of revenue

Research & development expense

Stock compensation expense

Depreciation and amortization expense

Selling, general and administrative expense

Loss from operations

Other income (expenses)

Income tax expense

Three months ended June 30, 2024, as compared to three months

ended June 30, 2023

Total Revenue.

We had revenues of $4,509,126

(comprising $4,258,198 of system sales, $204,121 of instrument sales, $28,795 of warranty sales and lease income $18,012), for the three

months ended June 30, 2024, compared to $1,891,813 (comprising $1,424,783 of system sales and $467,030 of instrument sales) for the three

months ended June 30, 2023.

The increase in net total is primarily due to sale of increased number of surgical robotic systems and instruments

in the period ended June 30, 2024 as compared to the period ended June 30, 2023.

Research and development expense.

Research and development expenses were $759,004 during the three months

ended June 30, 2024 as compared to $246,426 for the three months ended June 30, 2023.

Research and development expense primarily consists

of salaries paid to engineers, amounting to $431,920 and $151,560 for the period ended June 30, 2024 and 2023, respectively.

in research and development expenses as compared to the previous period is in line with the Company’s continued focus on improving

the design and technological capabilities of its existing SSi Mantra system and further expanding its product offerings.

Stock compensation expense.

We had compensation

expenses of $2,443,792 and $8,150 during three months ended June 30, 2024 and June 30, 2023, respectively.

The substantial increase in

the stock compensation expense in 2024 is primarily the result of the award of stock grants to employees of the subsidiaries and the issuance

of stock awards and stock options to executive officers of the Company and its subsidiaries in November 2023 under our Incentive Stock

Plan, in recognition of their efforts in developing and commercializing our SSi Mantra system.

Depreciation and amortization expense.

We had depreciation and amortization expense of $90,476 for the period ended June 30, 2024, as compared to $34,466 for the period

ended June 30, 2023.

The depreciation and amortization expenses primarily consist of depreciation on fixed assets only.

Selling, general and administrative expense.

We incurred $2,244,703 in general and administrative expenses during the three months ended June 30, 2024, as compared to $5,669,790,

June 30, 2023, respectively.

Our SG&A expense comprise of expense relating

to salaries and benefits, retirement benefits as well as costs related to recruitment, other compensation expenses of sales and marketing

and client management personnel, sales commission, travel and brand building, client events and conferences, training and retention of

senior management and other support personnel in enabling functions, telecommunications, utilities, travel and other miscellaneous administrative

S,G&A expense also include acquisition-related costs, legal and professional fees (which represent the costs of third party

legal, tax, accounting, immigration and other advisors), investment in product development, digital technology, advanced automation and

robotics, related to grant of our equity awards to members of our board of directors.

We expect our S,G&A expense to increase as we

continue to strengthen our support and enabling functions and invest in leadership development, performance management and training programs.

The decrease in S,G&A expense is due to non-cash

expense incurred relating to shares issued to investors and advisors during the period June 30, 2023.

Other income/expenses .

other expenses of $40,381 for the three months ended June 30, 2024, as compared to $333,353 of other expenses during the three months

ended June 30, 2023.

The reduction in interest expense from June 30, 2023 to June 30, 2024 resulted from an increase in interest income

on fixed deposits with HDFC bank in India.

We incurred a net loss of

$4,140,570 for the three months ended June 30, 2024, as compared to a net loss of $5,524,488 for the three months ended June 30, 2023.

The decrease in net loss from June 30, 2023 to June 30, 2024 is primarily the result of the decrease in general and administrative expenses

of $3,425,087 and increase in stock compensation expense of $2,435,642 on account of stock awards and options granted to the employees

and executive officers of the Company respectively.

For the Six months ended

(As restated)

1 unchanged sentence

Cost of revenue

Research & development

Research & development expense

Stock compensation expense

Depreciation and amortization

Selling, general and administrative

Depreciation and amortization expense

Selling, general and administrative expense

Loss from operations

(13,932,508 )

Other income (expenses)

Income tax expense

Three months ended March 31, 2024, as compared to three months

ended March 31, 2023

(13,982,323 )

Six months ended June 30, 2024, as compared to Six months

ended June 30, 2023

Total Revenue.

We had revenues of $8,146,819

(comprising $3,494,759 of system sales, $118,515 of instrument sales, $9,407 of warranty sales and $15,012 of lease income), for the three

months ended March 31, 2024, compared to $370,120 (comprising $355,414 of system sales, $14,706 of instrument sales) for the three months

ended March 31, 2023.

(comprising $7,752,957 of system sales, $322,636 of instrument sales, $38,202 of warranty sales and lease income $33,024), for the six

months ended June 30, 2024, compared to $2,261,933 (comprising $1,780,197 of system sales and $481,736 of instrument sales) for the six

months ended June 30, 2023.

The increase in net total is primarily due to sale of increased number of surgical robotic systems and instruments

during the three months ended March 31, 2024 as compared to three months ended March 31, 2023.

in the period ended June 30, 2024 as compared to the period ended June 30, 2023.

Research and development expense.

and development expenses were $527,991 during the three months ended March 31, 2024 and $242,127 for the three months ended March 31,

Research and development expense primarily consists of salaries paid to engineers, amounting to $191,487 and $209,991 for the period

ended March 31, 2024 and 2023, respectively.

The increase in the Research and development expenses as compared to the previous year is

in line with the Company’s continued focus on improving the design and technological capabilities of its existing SSi Mantra system

and further expanding its product offerings.

and development expenses were $1,286,995 during the six months ended June 30, 2024 as compared to $488,553 for the three months ended

June 30, 2023.

Research and development expense primarily consists of salaries paid to engineers, amounting to $618,471 and $297,123

for the period ended June 30, 2024 and 2023, respectively.

The increase in research and development expenses as compared to the previous

year is in line with the Company’s continued focus on improving the design and technological capabilities of its existing SSi Mantra

system and further expanding its product offerings.

Stock compensation expense.

compensation expenses of $7,108,750 and $nil for three months ended March 31, 2024 and March 31, 2023, respectively.

The substantial

increase in the stock compensation expense for three months ended March 31, 2024 is primarily the result of additional stock options

granted to executive officer of the Company in February 2024 under Incentive Stock Plan, in recognition of their efforts in developing

and commercializing our SSi Mantra system.

We had compensation

expenses of $9,552,542 and $8,150 during six months ended June 30, 2024 and June 30, 2023, respectively.

The substantial increase in the

stock compensation expense in 2024 is primarily the result of the award of stock grants to employees of the subsidiaries and the issuance

of stock awards and stock options to executive officers of the Company and its subsidiaries in November 2023 under our Incentive Stock

Plan, in recognition of their efforts in developing and commercializing our SSi Mantra system.

Depreciation and amortization expense.

We had depreciation and amortization expense of $80,101 for three months ended March 31, 2024, as compared to $32,591 for the period

ended March 31, 2023.

We had depreciation and amortization expense of $170,577 for the period ended June 30, 2024, as compared to $67,057 for the period

ended June 30, 2023.

The depreciation and amortization expenses primarily consist of depreciation on fixed assets only.

Selling, general and administrative expense.

We incurred $2,843,659 in general and administrative expenses during the three months ended March 31, 2024 as compared to $873,858

for the three months ended March 31, 2023, respectively.

We incurred $5,088,362 in general and administrative expenses during the six months ended June 30, 2024, as compared to $6,543,648,

June 30, 2023, respectively.

Our SG&A expense comprise of expense relating

2 unchanged sentences

senior management and other support personnel in enabling functions, telecommunications, utilities, travel and other miscellaneous administrative

SG&A expense also include acquisition-related costs, legal and professional fees (which represent the costs of third party

S,G&A expense also include acquisition-related costs, legal and professional fees (which represent the costs of third party

legal, tax, accounting, immigration and other advisors), investment in product development, digital technology, advanced automation and

robotics, related to grant of our equity awards to members of our board of directors.

We expect our SG&A expense to increase as we

We expect our S,G&A expense to increase as we

continue to strengthen our support and enabling functions and invest in leadership development, performance management and training programs.

The increase in SG&A expense resulted

from the increased scale of commercial operations for three months ended March 31, 2024 as compared to the three months ended March 31,

The decrease in S,G&A expense is due to non-cash

expense incurred relating to shares issued to investors and advisors during the period June 30, 2023.

Other income/expenses .

other expenses of $9,434 for the three months ended March 31, 2024 as compared to $242,387 of other expenses for three months ended March

The reduction in interest expense from March 31, 2023 to March 31, 2024 resulted from an increase in interest income on fixed

deposits with HDFC bank in India.

other expenses of $49,815 for the six months ended June 30, 2024, as compared to $575,740 of other expenses during the six months ended

June 30, 2023.

The reduction in interest expense from June 30, 2023 to June 30, 2024 resulted from an increase in interest income on

fixed deposits with HDFC bank in India.

We incurred a net loss of

$9,841,753 for three months ended March 31, 2024, as compared to a net loss of $1,313,016 for the three months ended March 31, 2023.

The increase in net loss from March 31, 2023 to March 31, 2024 is primarily the result of the increase in general and administrative

expenses of $1,969,801 and stock compensation expense of $7,108,750 on account of stock awards and options granted to the employees and

executive officers of the Company respectively.

$13,932,508 for the six months ended June 30, 2024, as compared to a net loss of $6,837,504 for the six months ended June 30, 2023.

increase in net loss from June 30, 2023 to June 30, 2024 is primarily the result of the decrease in general and administrative expenses

of $1,455,286 and increase in stock compensation expense of $9,544,392 on account of stock awards and options granted to the employees

and executive officers of the Company respectively.

Liquidity and Capital Resources

The Company expects to require substantial

funds for scaling up its operations, for incurring capital expenditure to have its own in-house machining and tooling capacity and to

continue to finance its research and development work in the field of surgical robotics.

The Company expects to require substantial funds

for scaling up its operations, for incurring capital expenditure to have its own in-house machining and tooling capacity and to continue

to finance its research and development work in the field of surgical robotics.

Between February 1, 2024, and February 14, 2024,

2024, the Company raised $2,450,000 million through a private offering of 7% One-Year Convertible Promissory Notes (“Notes”)

from two affiliates of $1,000,000 each and $450,000 from three other investors to finance its ongoing working capital requirements.

the Company raised $2,450,000 through a private offering of 7% One-Year Convertible Promissory Notes (“Notes”) from two affiliates

of $1,000,000 each and $450,000 from three other investors to finance its ongoing working capital requirements.

These Notes are payable in full after 12 months

2 unchanged sentences

In April 2024, the Company has raised $2,000,000

from Sushruta Pvt Ltd.

by issuance of two, One-Year 7% Promissory Notes of $1,000,000 each, to meet certain working capital needs.

from its affiliate by issuance of two One-Year 7% Promissory Notes of $1,000,000 each, to meet certain working capital needs.

While we have been successful in raising funds

7 unchanged sentences

and any such investment or other strategic alternative would likely substantially dilute our current shareholders.

For the Three months ended

For the six months ended

(As restated)

Net cash provided by operating activities:

(13,982,323 )

Non-cash adjustments

1 unchanged sentence

Net cash used in operating activities

Net cash used in investing activities

Net cash (used in) / provided by investing activities

Net cash provided by financing activities

4 unchanged sentences

Cash Flows from Operating Activities

During the three months ended March 31, 2024,

net cash used in operating activities was $1,249,038 resulting from our net loss of $9,841,753 partially offset by non-cash charges of

$7,598,648 primarily driven by credit loss reserve, depreciation charges and stock compensation expense.

We had cash provided by our

During the six months ended June 30, 2024,

net cash used in operating activities was $3,694,486 resulting from our net loss of $13,982,323 partially offset by non-cash charges

of $10,361,093 primarily driven by credit loss reserve, depreciation charges and stock compensation expense.

We had cash used in our

operating assets and liabilities of $73,476 primarily driven by increases in inventory, accounts payable and prepaid expenses.

During the three months ended March 31, 2023,

net cash used in operating activities was $2,484,722, resulting from our net loss of $1,313,016, partially offset by non-cash expenses

In 2023, we had cash used in our operating assets and liabilities of $1,452,352 primarily due to increases in accounts payable,

inventory and prepaid expenses.

During the six months ended June 30, 2023, net

cash used in operating activities was $5,376,506 resulting from our net loss of $6,837,504 partially offset by non-cash charges of $5,128,523

primarily driven by depreciation charges and stock compensation expense.

We had cash used in our operating assets and liabilities of $3,667,525

primarily driven by increases in inventory, accounts receivable and prepaid expenses.

Cash Flows from Investing Activities

During the three months ended March 31, 2024,

we had net cash used in investing activities of $1,550,135 in purchase of property and equipment.

During the three months ended March 31, 2023,

During the six months ended June 30, 2024,

we had net cash used in investing activities of $2,239,139 in purchase of property and equipment.

During the six months ended June 30, 2023, we

had net cash used in investing activities of $105,536 in purchase of property and equipment.

Cash Flows from Financing Activities

During the three-months ended March 31, 2024,

During the six months ended June 30, 2024,

we had net cash, provided by financing activities of $5,292,610, which comprised of $842,610 in proceeds from our bank overdraft facility

(net), $2,450,000 in proceeds from issuance of the convertible notes to our principal shareholder and other investors as set forth above.

During the three months ended March 31, 2023,

we had net cash used provided by financing activities of $2,616,260, which comprised of $740,358 in proceeds from our bank overdraft

facility (net), $2,000,000 in proceeds from issuance of convertible notes to principal shareholder.

There was a decrease of $124,098

on account of repayment of term loans.

(net), $4,450,000 in proceeds from issuance of convertible notes to principal shareholder and other investors as set forth above.

During the six-months ended June 30, 2023, we

had net cash, provided by financing activities of $5,759,682, which comprised of $1,677,577 in proceeds from our bank overdraft facility

(net), $1,225,000 in proceeds from issuance of convertible notes to principal shareholder, $3,000,000 in proceeds from issuance of convertible

notes to other investors and $142,895 on account of repayment of term loans.

While we have been successful in raising funds

to finance our operations since inception and we believe that we will be successful in obtaining the necessary financing to fund our

operations going forward, we do not have any committed sources of funding and there are no assurance that we will be able to secure additional

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a

going concern;

however, if we cannot obtain financing, then we may be forced to further curtail our operations or consider other strategic

alternatives.

Even if we are successful in raising the additional financing, there is no assurance regarding the terms of any additional

investment and any such investment or other strategic alternative would likely substantially dilute our current shareholders.

to finance our operations since inception and we believe that we will be successful in obtaining the necessary financing to fund our operations

going forward, we do not have any committed sources of funding and there are no assurance that we will be able to secure additional funding.

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern;

however, if we cannot obtain financing, then we may be forced to further curtail our operations or consider other strategic alternatives.

Even if we are successful in raising the additional financing, there is no assurance regarding the terms of any additional investment

and any such investment or other strategic alternative would likely substantially dilute our current shareholders.

Critical Accounting Policies

Use of Estimates

The preparation of condensed consolidated

financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates

and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the

date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.

Actual results could differ from those estimates.

The preparation of condensed consolidated financial

statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and

assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date

of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.

results could differ from those estimates.

Significant estimates included discount rate for measuring significant financing component

for deferred collections in revenue contracts, fair value of stock options, incremental borrowing rate for leases and useful life of

property plant and equipment.

for deferred collections in revenue contracts, fair value of stock options, incremental borrowing rate for leases and useful life of property

plant and equipment.

Off-Balance Sheet Arrangements

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q/A

Item 2. Management’s Discussion and Analysis